Isolated limb perfusion with TNF-α and melphalan in locally advanced soft tissue sarcomas of the extremities

Alexander M.M. Eggermont, Dirk J. Grünhagen, Johannes H.W. De Wilt, Albertus N. Van Geel, Cornelis Verhoef

Onderzoeksoutput: Hoofdstuk in Boek/Rapport/CongresprocedureHoofdstukpeer review

29 Citaten (Scopus)


Limb-sparing surgery has become all the more important in soft tissue sarcoma (STS) of the extremities since we learned that amputation does not improve survival of these patients. In bulky tumours, however, preoperative strategies to reduce tumour size are then required. Isolated limb perfusion (ILP) with tumour necrosis factor (TNF) has been developed as a biochemotherapeutic therapy to act both on the tumour-associated vasculature and on the tumour itself. It has shown to be a very potent treatment modality, as in early reports response rates were around 80%. Limb salvage could then be achieved in a quite similar percentage. Many confirmatory studies have been performed since, with consistent results even in patients with multiple tumours, after extensive radiotherapy or with metastatic disease, all at the cost of very limited toxicity. This chapter gives an overview of the ILP studies performed in patients with soft tissue limb sarcoma, discusses the mechanism of TNF-mediated vasculotoxic effects on tumour vasculature, and places TNF-based ILP in the multimodality treatment of these patients with extensive STS of the extremities.

Originele taal-2Engels
TitelTreatment of Bone and Soft Tissue Sarcomas
Aantal pagina's14
StatusGepubliceerd - 2009
Extern gepubliceerdJa

Publicatie series

NaamRecent Results in Cancer Research
ISSN van geprinte versie0080-0015


Duik in de onderzoeksthema's van 'Isolated limb perfusion with TNF-α and melphalan in locally advanced soft tissue sarcomas of the extremities'. Samen vormen ze een unieke vingerafdruk.

Citeer dit